



RECOGNISING THE CONTRIBUTIONS OF THE ACE CONSUMER PANEL



The ACE Consumer Panel met on 10 March 2026 to celebrate key consumer engagement achievements over the past year and to provide an opportunity for Panel members to reflect on their experiences and aspirations for the Panel. ACE also hosted an appreciation dinner to thank Panel members for their valuable contributions.

Over the past term, the Panel has played a key role in shaping ACE's patient involvement initiatives and helping to ensure that patient voices are reflected in healthcare decision-making.

Click [here](#) to see highlights of their contributions.



NEW HTA LEARNING MODULES FOR PATIENTS AND THE PUBLIC



The CEE team has developed two short learning modules that explain key aspects of HTA in plain language and support self-directed learning. The ACE Consumer Panel provided feedback during the development of the modules to ensure the content is useful and relevant for patients.

How is clinical effectiveness assessed in health technology assessment (HTA)?

This module introduces the concepts of clinical efficacy, clinical effectiveness and clinical importance, and provides an overview on how information is gathered to determine clinical effectiveness in an HTA.

To download the module


CLICK HERE ✨

How is the PICO framework used in health technology assessment (HTA)?

This module explains each component of the PICO (population, intervention, comparator, outcome) framework and how it is used to define research questions in HTA.

To download the module

CLICK HERE ✨



These modules also include simple quizzes to reinforce key concepts.

Stay tuned for more learning modules coming soon!

PUBLICATIONS ON ACE'S PATIENT INVOLVEMENT PROCESSES

Two articles published in the *International Journal of Technology Assessment in Health Care (IJTAHC)*

Patient Involvement in Health Technology Assessment: A New Process in Singapore



Find out more

This article describes ACE's journey in establishing formal processes for patient involvement in HTA. It outlines ACE's structured approach to stakeholder mapping, co-developing processes with local patient organisations, and building capacity for meaningful participation.


Establishing a Consumer Panel to Inform Health Technology Assessment Processes and Policy: Impact and insights from Singapore's Experience



Find out more

This article outlines ACE's approach to establishing the Consumer Panel, highlights the Panel's contributions during its inaugural term, and shares members' reflections on their roles and future directions for advancing patient partnership in HTA. Two Panel members contributed to the article as co-authors.

Patient Involvement in Health Technology Assessment (Second edition)



Find out more

Chapter 23 Singapore: From Stakeholder Mapping to Continuously Improving Patient Participation in HTA

Fiona Pearce, Ping-Te Tan, and Josie Liow

Local patient organisations also value the opportunity to participate in the HTA process and consider it to be a meaningful and important activity for their members. Some patient organisations have even appointed dedicated staff and resources to coordinate patient input into HTAs.

The SingHealth Patient Advocacy Network (SPAN) has worked closely with ACE since 2021 to provide the patient's perspective in healthcare decision-making. To ensure dedicated resources for the regular engagements, an internal workgroup comprising patient advocates was formed to support the collaboration. It has been an enlightening experience sharing personal insights from our patient and caregiver journeys, and using our knowledge to provide feedback, with the aim of improving healthcare quality. The partnership has empowered patient advocates to take on active roles in shaping healthcare policies by offering their voices as users of healthcare. Involving the patient's voice in the review of disease-specific factsheets was also a significant move in enabling patients and families to make informed healthcare decisions, thereby improving health literacy. We are certainly in the right direction towards healthcare that is truly for patients, by patients.
—Josie Liow, Co-Chair SingHealth Patient Advocacy Network (SPAN)

The second edition of the Patient Involvement in Health Technology Assessment (HTA) book features insights from over 120 authors across the globe, showcasing diverse experiences and practical approaches to advancing patient involvement in HTA. It is an open access (free) resource. Be sure to check out Chapter 23, authored by ACE, which explores patient involvement approaches in Singapore. The chapter also includes a personal reflection from an ACE Consumer Panel member.

1

Patient education aid published in February 2026

- Common questions on atopic dermatitis

Patient education aids are co-developed with patient organisations and clinicians to support the implementation of ACE Clinical Guidelines by providing patients with simple, helpful information about different health conditions, treatments, medical tests and tips for better self-management.




[Find out more](#)



PLAIN ENGLISH SUMMARIES

NEW



17

Plain English summaries published since February 2026

Plain English summaries (PES) provide brief information about the health technologies and conditions that have been evaluated by ACE and describe the key funding recommendations made by the MOH advisory committees.

[Find out more](#)



New:

- Amivantamab for treating locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer
- Capivasertib in combination with fulvestrant for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN-alteration
- Complement inhibitors for treating paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome
- Donanemab and lecanemab for treating early Alzheimer’s disease
- Eplontersen and vutrisiran for treating hereditary transthyretin amyloidosis with polyneuropathy
- Inavolisib in combination with palbociclib and fulvestrant for treating PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer
- Positive airway pressure for moderate-to-severe obstructive sleep apnoea
- Ribociclib for adjuvant treatment of HR-positive, HER2-negative early breast cancer

- Talquetamab for relapsed or refractory multiple myeloma
- Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric cancer

Updated:

- Asciminib for previously treated Philadelphia chromosome-positive chronic myeloid leukaemia
- Biologics as add-on therapy for severe asthma
- Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
- Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
- Nivolumab for treating gastroesophageal cancers
- Sodium zirconium cyclosilicate for treating hyperkalaemia
- Toripalimab for treating recurrent or metastatic nasopharyngeal carcinoma

PATIENT FACTSHEETS

1

Patient factsheet published in April 2026

- Positive airway pressure systems for obstructive sleep apnoea (new)



Find out more



PATIENT INPUT

Over

80

Patient responses were gathered for topics presented to the MOH advisory committees in November 2025



The effort put in by patients to share their experiences is appreciated and every input is valuable to ACE and MOH. The CEE team notifies patient organisations of the advisory committees' funding recommendations after each meeting and provides feedback on which information provided by patients was most helpful to inform the committees' deliberations. The CEE team also invites suggestions on how the patient involvement processes can be improved through this [link](#).

SHARING ACE'S APPROACH TO PATIENT INVOLVEMENT REGIONALLY



Global vs Asia-Pacific findings from HTAi 360 studies
CIRS Workshop – 3 March 2026

Fiona Pearce
Co-Chair, HTAi Patient and Citizen Involvement in HTA Interest Group (PCIG)



CIRS HTA Agency Forum and Patient Involvement Workshop, 3-5 March 2026

The CEE team participated in discussions on HTA processes and collaborations at the Centre for Innovation in Regulatory Science (CIRS) HTA Agency Forum, and presented Singapore's patient involvement practices in HTA at a workshop organised by CIRS and Duke-NUS Centre of Regulatory Excellence (CoRE). The workshop was attended by representatives from regulatory agencies, HTA bodies, industry, academia, and patient organisations to explore patient-centred practices and strategies that strengthen healthcare decision-making across the Asia Pacific region.



The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidelines and education.

The Consumer Engagement and Education (CEE) team supports patient involvement in ACE's work and co-develops plain English summaries and educational resources with patient organisations to improve health literacy and encourage shared healthcare decision-making between patients and their doctors.

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore.

Published on 24 April 2026 To find out more about ACE, scan the QR code or visit www.ace-hta.gov.sg. You can also follow us on social media at:

